A 36-year-old female client presents to the psychiatric-mental health nurse practitioner. She has been stable for 1 year but says her buprenorphine regimen has not been working since she started a new medication prescribed by her primary care provider. Which medication most likely contributed to the decrease in buprenorphine efficacy?

Choice A reason: Carbamazepine is a potent inducer of cytochrome P450 enzymes, particularly CYP3A4, which metabolizes buprenorphine. This induction accelerates buprenorphine clearance, reducing its plasma concentration and therapeutic effect. Clinical evidence supports that co-administration can lead to subtherapeutic levels and relapse risk. Choice B reason: Amitriptyline is a tricyclic antidepressant that does not significantly affect buprenorphine metabolism. While it may contribute to sedation or other side effects, it does not reduce buprenorphine efficacy. Choice C reason: Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and a CYP2D6 inhibitor. It does not significantly impact buprenorphine metabolism via CYP3A4 and is unlikely to reduce its efficacy. Choice D reason: Erythromycin is a CYP3A4 inhibitor, which could potentially increase buprenorphine levels rather than decrease them. It is not associated with reduced efficacy of buprenorphine.